Updates in the Management of Myasthenia Gravis Peers and Perspectives

James F. Howard Jr., MD and Nicholas J. Silvestri MD, FAAN discuss an overview of myasthenia gravis and important tools for diagnosis of myasthenia gravis.

Expert panelists discuss misdiagnosis of myasthenia gravis and consider the question of whether this condition should be treated by community physicians.

Thought leaders offer practical advice on setting therapy goals for patients with myasthenia gravis, with an emphasis on patient inclusion.

James F. Howard Jr., MD and Nicholas J. Silvestri MD, FAAN, share insights regarding acetylcholinesterase inhibitors and immunosuppressive therapy as first-line treatments for patients with myasthenia gravis.

Two subject matter experts discuss cases where a thymectomy is appropriate for treating patients with myasthenia gravis.

Recommendations from neurologists James F. Howard Jr., MD and Nicholas J. Silvestri MD, FAAN for addressing acute exacerbation in patients with myasthenia gravis.

Experts recommend approaches for special cases including ocular myasthenia gravis, pregnant patients and children with myasthenia gravis, and more.

A comprehensive review of drugs to avoid when designing treatment plans for patients with myasthenia gravis.

Thought leaders review the role of non-pharmacological strategies to manage myasthenia gravis comorbidities.

James F. Howard Jr., MD, and Nicholas J. Silvestri MD, FAAN, review the role of complement inhibitors and FcRn inhibitors in the management of myasthenia gravis.

Experts discuss the benefits of complement inhibitors in reducing symptoms of myasthenia gravis.

James F. Howard Jr., MD and Nicholas J. Silvestri MD, FAAN, discuss the efficacy and safety of FcRn inhibitors, as well as consider their role in the rapidly evolving treatment landscape.

Two subject matter experts discuss promising treatment methods and agents in the pipeline for patients with myasthenia gravis.

James F. Howard Jr., MD, and Nicholas J. Silvestri MD, FAAN, deliver parting thoughts on the state of the myasthenia gravis treatment, focusing on current deficits and future prospects.